These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR). Hubbard RD; Bamaung NY; Palazzo F; Zhang Q; Kovar P; Osterling DJ; Hu X; Wilsbacher JL; Johnson EF; Bouska J; Wang J; Bell RL; Davidsen SK; Sheppard GS Bioorg Med Chem Lett; 2007 Oct; 17(19):5406-9. PubMed ID: 17689078 [TBL] [Abstract][Full Text] [Related]
45. Augmentation of Smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice. Komatsu Y; Yu PB; Kamiya N; Pan H; Fukuda T; Scott GJ; Ray MK; Yamamura K; Mishina Y J Bone Miner Res; 2013 Jun; 28(6):1422-33. PubMed ID: 23281127 [TBL] [Abstract][Full Text] [Related]
46. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines. Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146 [TBL] [Abstract][Full Text] [Related]
48. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy. Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969 [TBL] [Abstract][Full Text] [Related]
49. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation. Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108 [TBL] [Abstract][Full Text] [Related]
50. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach. Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081 [TBL] [Abstract][Full Text] [Related]
51. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity. Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and cytotoxicity studies of Hedgehog enzyme inhibitors SANT-1 and GANT-61 as anticancer agents. Chenna V; Hu C; Khan SR J Environ Sci Health A Tox Hazard Subst Environ Eng; 2014; 49(6):641-7. PubMed ID: 24521409 [TBL] [Abstract][Full Text] [Related]
54. Improving recombinant bone morphogenetic protein-4 (BMP-4) production by autoregulatory feedback loop removal using BMP receptor-knockout CHO cell lines. Kim CL; Lee GM Metab Eng; 2019 Mar; 52():57-67. PubMed ID: 30447330 [TBL] [Abstract][Full Text] [Related]
55. BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma. Strong AL; Spreadborough PJ; Dey D; Yang P; Li S; Lee A; Haskins RM; Grimm PD; Kumar R; Bradley MJ; Yu PB; Levi B; Davis TA Stem Cells Dev; 2021 Jan; 30(2):91-105. PubMed ID: 33256557 [TBL] [Abstract][Full Text] [Related]
56. Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification. Gomez-Stallons MV; Wirrig-Schwendeman EE; Hassel KR; Conway SJ; Yutzey KE Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1398-405. PubMed ID: 27199449 [TBL] [Abstract][Full Text] [Related]
57. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Klotz KN; Leung E; Varani K; Gessi S; Merighi S; Borea PA J Med Chem; 1999 Nov; 42(22):4473-8. PubMed ID: 10579811 [No Abstract] [Full Text] [Related]
58. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. Tsugawa D; Oya Y; Masuzaki R; Ray K; Engers DW; Dib M; Do N; Kuramitsu K; Ho K; Frist A; Yu PB; Bloch KD; Lindsley CW; Hopkins CR; Hong CC; Karp SJ J Pharmacol Exp Ther; 2014 Dec; 351(3):549-58. PubMed ID: 25271257 [TBL] [Abstract][Full Text] [Related]
59. Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. Shen HC; Taggart AK; Wilsie LC; Waters MG; Hammond ML; Tata JR; Colletti SL Bioorg Med Chem Lett; 2008 Sep; 18(18):4948-51. PubMed ID: 18752940 [TBL] [Abstract][Full Text] [Related]
60. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1. Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]